Mr. Thomas Smeenk reports

HEMOSTEMIX ENGAGES PATENTVEST TO STRENGTHEN ITS GLOBAL PATENT PORTFOLIO

Hemostemix Inc. has struck a partnership with PatentVest.

PatentVest, a subsidiary of MDB Capital (Nasdaq: MDBH), is a premier intellectual property strategy and patent prosecution firm specializing in life sciences.

The engagement underscores Hemostemix's commitment to expanding its intellectual property portfolio to drive innovation and shareholder value. PatentVest will provide Hemostemix with a comprehensive strategic intellectual property support program, including:

• Evaluating and optimizing Hemostemix's existing patent portfolio to ensure alignment with research and development, and commercialization objectives;

• Identifying and securing patentable claims for new therapeutic innovations;

• Developing and executing global filing strategies to strengthen Hemostemix's intellectal property (IP) footprint in key markets;

• Enhancing the company's value by positioning it to attract strategic partners, expand licensing opportunities and command premium valuations in the biotechnology sector.

"Our collaboration with PatentVest is a strategic step forward to secure additional intellectual property rights and amplify the value of our existing patents," stated Thomas Smeenk, chief executive officer, Hemostemix. "PatentVest is accepting partial payment in equity, which aligns its incentives with the long-term success of Hemostemix shareholders. This collaboration unlocks the full potential of our innovations and maximizes our market opportunities," Mr. Smeenk said.

Will Rosellini, chief intellectual property officer of PatentVest, commented: "By applying our time-tested leadership development process to build upon the company's meaningful IP portfolio, Hemostemix will be well positioned with a strong, defensible position in scalable autologous stem cell treatments for cardiovascular diseases. We are exploring opportunities to extend the terms of Hemostemix's patents based on its ongoing FDA studies, potentially prolonging market exclusivity for its groundbreaking therapies. Additionally, Hemostemix's license of the automated bioreactor technology promises to significantly reduce production costs, making treatments more accessible and scalable. This partnership strengthens Hemostemix's IP strategy, and positions the company to transform cardiovascular treatment affordability and drive exponential shareholder value," Mr. Rosellini added.

About PatentVest

PatentVest, a division of MDB Capital Holdings, is the first integrated IP intelligence, strategy and law firm that enables visionary companies to develop into technology leaders. By combining its proprietary database with its proven IP diligence process and expert analysis, it delivers actionable insights on the IP landscape to help its clients make informed decisions and stay ahead of the curve. The trends and competitive insights in this report are powered by PatentVest's proprietary IP intelligence platform. Its reports keep a pulse on the key players, technologies and opportunities shaping deep technology markets.

About Hemostemix Inc.

Hemostemix is an autologous stem cell therapy platform company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the company has developed, patented, is scaling and selling autologous (patient's own) blood-based stem cell therapies that include angiogenic cell precursors (ACP-01), later neural cell precursors (NCP-01) and cardiomyocyte cell precursors (CCP-01).

We seek Safe Harbor.